A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...
Epsom General Hospital, Epsom, Surrey, United Kingdom
Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom
University of Cambridge, Cambridge, England, United Kingdom
Royal London Hospital, London, England, United Kingdom
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
St. Thomas' Hospital, London, England, United Kingdom
Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
Siouxland Hematology-Oncology, Sioux City, Iowa, United States
CCOP - Wichita, Wichita, Kansas, United States
Mayo Clinic, Rochester, Minnesota, United States
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center, West Palm Beach, Florida, United States
Saint John Regional Hospital, Saint John, New Brunswick, Canada
Toronto Sunnybrook Regional Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Hopital Charles Lemoyne, Greenfield Park, Quebec, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.